[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538349":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":59,"centralContacts":63,"locations":69,"responsibleParty":118,"collaborators":67,"id":120,"slug":121,"hasResults":122,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":67,"eligibilityCriteria":126,"healthyVolunteers":122,"sex":127,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":67,"studyType":133,"phases":134,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":72,"whyStopped":67,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"St. Jude Children's Research Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Newly diagnosed ALL, LLy, and MPAL patients","EXPERIMENTAL","All eligible patients receive the following intervention:\n\nDexamethasone, Vincristine, Daunorubicin, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)",[13,14,15,16,17,18],"Drug: Dexamethasone","Drug: Vincristine","Drug: Daunorubicin","Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)","Drug: Methotrexate","Drug: Cytarabine",[20,27,34,40,46,53],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dexamethasone","Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7",[9],[26],"Decadron",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Vincristine","Intravenously (IV) for 1 dose on Day 1 or 2",[9],[32,33],"Vincristine Sulfate","Oncovin",{"type":21,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Daunorubicin","Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL\u002F T-LLy\u002F MPAL only)",[9],[39],"Daunomycin",{"type":21,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)","Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6",[9],[45],"ITMHA",{"type":21,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"Methotrexate","Given IT as part of Intrathecal triple therapy.",[9],[51,52],"MTX","Trexall®",{"type":21,"name":54,"description":48,"armGroupLabels":55,"otherNames":56},"Cytarabine",[9],[57,58],"Cytosine arabinoside","Ara-C",[60],{"name":61,"affiliation":5,"role":62},"Seth E. Karol, MD","PRINCIPAL_INVESTIGATOR",[64],{"name":61,"role":65,"phone":66,"phoneExt":67,"email":68},"CONTACT","888-226-4343",null,"referralinfo@stjude.org",[70,90,106],{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Rady Children's Hospital","RECRUITING","San Diego","California","92123","United States","US",{"type":79,"coordinates":80},"Point",[81,82],-117.16472,32.71571,{"lat":82,"lon":81},[85,89],{"name":86,"role":65,"phone":87,"phoneExt":67,"email":88},"Victor Wong, MD","858-966-5811","vwong@rchsd.org",{"name":86,"role":62,"phone":67,"phoneExt":67,"email":67},{"facility":91,"status":72,"city":92,"state":93,"zip":94,"country":76,"countryCode":77,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Saint Francis Children's Hospital","Tulsa","Oklahoma","74136",{"type":79,"coordinates":96},[97,98],-95.99277,36.15398,{"lat":98,"lon":97},[101,105],{"name":102,"role":65,"phone":103,"phoneExt":67,"email":104},"Ashraf Mohamed, MD","918-502-6720","ammohamed@saintfrancis.com",{"name":102,"role":62,"phone":67,"phoneExt":67,"email":67},{"facility":5,"status":72,"city":107,"state":108,"zip":109,"country":76,"countryCode":77,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Memphis","Tennessee","38105",{"type":79,"coordinates":111},[112,113],-90.04898,35.14953,{"lat":113,"lon":112},[116,117],{"name":61,"role":65,"phone":66,"phoneExt":67,"email":68},{"name":61,"role":62,"phone":67,"phoneExt":67,"email":67},{"type":119,"investigatorFullName":67,"investigatorTitle":67,"investigatorAffiliation":67,"oldNameTitle":67,"oldOrganization":67},"SPONSOR","100538349","phase-4-identification-of-necessary-information-for-treatment-induction-in-newly-diagnosed-acute-lymphoblastic-leukemialymphoma-100538349",false,"NCT06289673","Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia\u002FLymphoma","INITIALL: Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia\u002FLymphoma","Inclusion Criteria:\n\n* Age 1-18.99 years\n* Diagnosis of acute leukemia \u002F lymphoma as below:\n\n  * Acute lymphoblastic leukemia (ALL) with at least 25% bone marrow blasts or definitive evidence of ALL in peripheral blood (in those without an available bone marrow sample).\n  * Lymphoblastic lymphoma (LLy) with immunophenotypic evidence of a lymphoblastic population and \\\u003C25% bone marrow blasts and less than 1,000 circulating blasts\u002F microL.\n  * Mixed phenotype acute leukemia (MPAL) with or without 25% bone marrow involvement (i.e. patients with either leukemia or lymphoma are eligible).\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Receipt of prior cancer directed therapy with the exclusion of up to 1 dose of intrathecal chemotherapy, 1 dose of vincristine, or emergency radiotherapy due to organ compromising malignant mass. There is no exclusion for prior steroid therapy.\n* Known to be currently ineligible for available SJALL therapeutic studies (e.g. receipt of prohibited therapy, no appropriate SJALL therapeutic study available, enrolled on competing trial, etc.).\n\nNote: The intention of this exclusion criterion is to enroll all newly diagnosed ALL\u002F LLy\u002F MPAL patients. If participant is screened as a potential participant for subsequent SJALL and later found to be ineligible due to information obtained during INITIALL, this will not make the participant ineligible for INITIALL.\n\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.\n* Major pre-existing abnormalities such as ataxia telangiectasia, Fanconi anemia, Charcot Marie Tooth, etc.","ALL","1 Year","18 Years",{"count":131,"type":132},850,"ESTIMATED","INTERVENTIONAL",[135],"PHASE4","The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term \"risk\" refers to the chance of the ALL or LLy coming back after treatment.\n\nPrimary Objectives\n\n* To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia\u002Flymphoma and mixed phenotype acute leukemia\u002Flymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies.\n* To develop a central database of genomic and clinical findings.\n\nSecondary Objectives\n\n* To assess event free and overall survival data of patients enrolled on this study.",[138,139,140],"Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma","Mixed Phenotype Acute Leukemia",[142,143,138,139,144,145,146],"Newly Diagnosed","Risk Category","Mixed Phenotype Acute Leukemia (MPAL)","Children","Young Adults","2026-04-29",{"date":149,"type":150},"2026-05-01","ACTUAL",{"date":152,"type":150},"2024-12-26",{"date":154,"type":132},"2039-05",{"name":5,"class":6},3]